Roger S McIntyre

Roger S McIntyre, MD, FRCPC

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and the Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

Dr. McIntyre was named by Thomson Reuters in 2014 as one of “The World’s Most Influential Scientific Minds”. This distinction is bestowed upon researchers who publish the most highly cited articles in a variety of scientific fields during the previous decade.

Dr. McIntyre is extensively involved in medical education.  He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto’s Department of Psychiatry and has been selected for the joint Canadian Psychiatric Association (CPA)/Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University and completed his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity.  Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
BMC Res Notes. 2016;9(1):340
Subramaniapillai M, Arbour-Nicitopoulos K, Duncan M, McIntyre RS, Mansur RB, Remington G, Faulkner G
Curr Opin Pharmacol. 2016 Jul 8;29:63-69
Rosenblat JD, Gregory JM, McIntyre RS
Ther Adv Chronic Dis. 2016 May;7(3):153-9
McIntyre RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, Gallaugher LA, Dale RS, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho A, Kennedy S
Bipolar Disord. 2016 Jun;18(4):373-8
Mansur RB, Santos CM, Rizzo LB, Asevedo E, Cunha GR, Noto MN, Pedrini M, Zeni-Graiff M, Cordeiro Q, Vinberg M, Kapczinski F, McIntyre RS, Brietzke E
J Psychiatr Res. 2016 May 28;80:38-44
Mansur RB, Rizzo LB, Santos CM, Asevedo E, Cunha GR, Noto MN, Pedrini M, Zeni-Graiff M, Gouvea ES, Cordeiro Q, Reininghaus EZ, McIntyre RS, Brietzke E
Lancet Psychiatry. 2016 Jun;3(6):499
Harrison JE, Lam RW, Baune BT, McIntyre RS



Head, Mood Disorders Psychopharmacology Unit, UHN
Professor, Departments of Psychiatry and Pharmacology and Toxicology, University of Toronto